Breaking Down Kuraray Co., Ltd. Financial Health: Key Insights for Investors

Kuraray Co., Ltd. (3405.T) presents a study in contrasts that every investor should examine: fiscal 2024 net sales rose by 5.9% to ¥826,895 million even as first-half 2025 net sales fell 2.7% to ¥399,958 million amid inventory valuation shifts and sluggish demand in Europe and the U.S.; operating income grew to ¥75,000 million (+12.7% in 2024) but plunged 42.2% to ¥26,261 million in H1 2025, while net income slipped to ¥31,724 million (‑25.3%) and the net profit margin dropped to 3.84% from 6.5% a year earlier; balance-sheet metrics show a solid equity ratio of 59.22% and a modest debt-to-equity of 0.32 with total cash of ¥111,256 million as of June 30, 2024, cash-generation remains healthy (operating cash flow to net income 4.36) even as free cash flow softened, valuation indicators (trailing P/E 26.53, forward P/E 9.69, EV/EBITDA 4.67, EV/Sales ~0.84-0.91) point to potential upside, and management has cut FY2025 net sales guidance to ¥810,000 million (from ¥840,000 million) while maintaining ambitious targets under PASSION 2026 toward ¥900 billion in sales and ¥110 billion in operating income-read on to unpack what these figures mean for risk, value and upside.

Kuraray Co., Ltd. (3405.T) - Revenue Analysis

• Primary drivers of the H1 2025 decline: inventory valuation differences, higher raw material and fuel prices, and stagnant demand in Europe and the United States.
• Segment performance: significant income drops in Vinyl Acetate and Functional Materials; improvement in Isoprene driven by operational stabilization in Thailand.
• Others segment: net sales of ¥50,863 million in 2024, up 11.4% year-on-year.

• Segment notes: Vinyl Acetate - sharp income decline; Functional Materials - notable profitability pressure; Isoprene - recovery as Thailand operations stabilized.
• Market context: cost inflation and weak demand in key Western markets contributed materially to near-term revenue softness.

Kuraray Co., Ltd. (3405.T) - Profitability Metrics

Key profitability indicators for Kuraray Co., Ltd. (3405.T) show a mixed picture: full-year 2024 operating performance improved while net profitability and first-half 2025 results weakened materially.

• Operating income (FY 2024): increased 12.7% to ¥75,000 million from ¥66,500 million in 2023.
• Operating income (H1 2025): decreased 42.2% to ¥26,261 million from ¥45,500 million in H1 2024.
• Net income attributable to owners (FY 2024): decreased 25.3% to ¥31,724 million from ¥42,500 million in 2023.
• Net profit margin (FY 2024): 3.84%, down from 6.5% in 2023.
• EBIT margin (FY 2024): 10.29% - effectively stable year-over-year.
• EBITDA margin (FY 2024): 20.60%, indicating healthy underlying operating cash generation.

• Interpretation: FY 2024 shows resilient operational margins (EBIT/EBITDA), but the large drop in H1 2025 operating income and the decline in net profit margin suggest rising costs, non-operating impacts, or one-off items compressing bottom-line returns.
• Investor focus areas: margin drivers (raw materials, energy, pricing), non-operating items affecting net income, and whether H1 2025 weakness is cyclical or structural.

Background and broader context on the company: Kuraray Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Kuraray Co., Ltd. (3405.T) - Debt vs. Equity Structure

• The equity ratio of 59.22% signals that shareholders' funds finance the majority of assets, reducing solvency risk.
• A debt-to-equity ratio of 0.32 indicates moderate use of debt - leverage is present but not excessive.
• ROE at 4.15% suggests the company may be underutilizing equity to generate higher returns for shareholders.

• Implication for creditworthiness: lowish leverage supports stronger credit metrics and greater capacity to absorb shocks.
• Implication for investors: high equity cushion reduces bankruptcy risk but modest ROE points to potential efficiency or margin pressures.

Kuraray Co., Ltd. (3405.T) - Liquidity and Solvency

As of June 30, 2024, Kuraray reported total cash of ¥111,256 million, reflecting a strong short-term liquidity buffer. Key cash-flow ratios show robust cash generation but a modest decline in free cash flow year-over-year.

• Total cash (Jun 30, 2024): ¥111,256 million
• Free cash flow (FCF) change 2023→2024: -2.67%
• Operating cash flow (OCF) to net income ratio: 4.36
• Free cash flow to net income ratio: 2.11
• Stable cash flow generation expected to support existing financial structure

Practical implications for investors:

• A large cash balance (¥111,256m) reduces short-term liquidity risk and provides flexibility for capex, dividends, or debt management.
• OCF substantially exceeds net income (4.36x), indicating high quality of reported earnings and strong operating cash conversion.
• FCF to net income (2.11x) is positive but lower, signaling that capital spending and working capital absorb a meaningful portion of cash generated.
• A small decline in FCF (-2.67%) warrants monitoring but is not immediately alarming given the absolute cash reserves and stable cash flow profile.

For more context on the company's background and strategy, see Kuraray Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Kuraray Co., Ltd. (3405.T) - Valuation Analysis

• Trailing P/E: 26.53 (as-reported, 7/4/2025)
• Forward P/E: 9.69 (consensus forward estimate)
• Price-to-Sales (P/S): ¥0.71
• Price-to-Book (P/B): ¥0.80
• Enterprise Value / Revenue (EV/Rev): 0.91
• Enterprise Value / EBITDA (EV/EBITDA): 4.67
• Enterprise Value / Sales for FY2025: 0.84

• Despite a relatively elevated trailing P/E, the much lower forward P/E suggests the market expects a meaningful rebound or margin expansion.
• Enterprise-value metrics (EV/Rev 0.91; EV/EBITDA 4.67; EV/Sales FY2025 0.84) point to one of the most undervalued positions in its sector when valuing the whole capital structure rather than equity alone.
• Price-to-book below 1.0 indicates the equity market values Kuraray at a discount to reported net assets; combined commentary notes the company "appears to be poorly valued given its net asset value."
• The gap between current market price and the average analyst target implies a significant upside potential should fundamentals align with analyst expectations.

Kuraray Co., Ltd. (3405.T) - Risk Factors

• Increased depreciation costs have reduced headline profits and compress operating leverage.
• Global economic uncertainty and U.S. tariff policies have intensified volatility and risk to export volumes.
• Weak overseas demand-notably in Europe and the United States-has contributed to stagnating sales in key segments.
• First‑half 2025 net sales declined due to inventory valuation differences, higher raw material and fuel prices, and subdued demand in major markets.
• Management revised the full‑year 2025 net sales forecast to ¥810,000 million, down from the prior ¥840,000 million guidance.

• Profitability trend: the drop from 6.50% to 3.84% net profit margin signals either elevated expenses (depreciation, input costs) or operational inefficiencies that warrant monitoring.
• Operating resilience: a stable EBIT margin of 10.29% in 2024 suggests underlying operating performance held up despite margin squeeze at the net level.
• Forecast sensitivity: the ¥30,000 million downward revision to FY2025 net sales highlights exposure to inventory accounting, commodity prices, and demand shifts.

Kuraray Co., Ltd. (3405.T) - Growth Opportunities

• Medium-term targets revised upward: net sales target raised to ¥900 billion and operating income target to ¥110 billion for FY2026.
• FY2025 guidance reflects near-term growth: net sales ¥860 billion (+4.0% vs FY2024) and operating income ¥90 billion (+5.8% vs FY2024).
• Net income is expected to rise materially to ¥45 billion in FY2025, driven by portfolio mix improvements and cost control.
• Capital investments (decision basis) of ¥120 billion in FY2025 focused on capacity for optical-use poval (poval film), activated carbon expansion, and dental materials growth.
• Intent to exceed FY2026 targets via continued organic investment and selective strategic investments.

• Capacity expansions: new facilities for optical-use poval film to capture demand in display/optics markets.
• Growth investments: scaling activated carbon capacity for environmental and industrial applications.
• Portfolio optimization: prioritizing higher-margin specialty and dental materials businesses.
• Disciplined capital allocation: ¥120 billion FY2025 capex plan with emphasis on projects with clear IRR and market pull.
• Operational improvements: margin recovery through cost controls and efficiency gains to drive operating income toward ¥110 billion by FY2026.